You are here
Home > Neuralstem

Neuralstem Announces Publication of a Study Showing Benefits of Neural Stem Cell (NSC) Transplantation in a Mouse Model of Alzheimer’s Disease

NSC transplantation led to improved cognition and reduced Aβ plaque pathology GERMANTOWN, Md., Oct. 25, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Scientific Reports showing that transplantation of NSI-532.IGF1, a proprietary human neural stem cell line […]

CORRECTING and REPLACING — Neuralstem, Inc.

GERMANTOWN, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) — In a release issued yesterday by Neuralstem, Inc. (Nasdaq:CUR), please note the headline should be, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke,” rather than, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke,” as originally issued. The corrected […]

Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke

GERMANTOWN, Md., July 31, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced the initiation of a Phase 2 clinical trial evaluating NSI-566, the Company’s lead neural stem cell candidate, as a potential treatment for ischemic stroke. […]

Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

GERMANTOWN, Md., June 11, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop […]

Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete paraplegia

– Neuralstem Announces Publication of Data From First-In-Human Study of Human Neural Stem Cell Transplantation for Chronic Spinal Cord Injury – – First cohort of four subjects with thoracic (T2-T12) ASIA-A grade spinal cord injury in the Phase I study received intraspinal injections of human spinal cord-derived neural stem cells 12-24 months after injury – […]

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

Post-hoc comparison of combined cohorts from Phase 1 and 2 trials vs. historical controls revealed statistically significant difference in scores in functional status and in a composite statistic combining survival and functional status in subjects receiving human spinal cord-derived neural stem cells Study provides validation for additional trials to evaluate the benefit of neural stem […]

Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day

GERMANTOWN, Md., April 11, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem, will be providing a clinical update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day at the Metropolitan Club […]

Top